Neurogenic Bladder Clinical Trial
— ICODEOfficial title:
Site of Implantation of Continent Catheterizable Channel : Native Bladder or Enterocystoplasty ? Comparison in 106 Patients
Verified date | June 2021 |
Source | Central Hospital, Nancy, France |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
PURPOSE. To compare the results between two sites of implantation of the continent catheterizable channel (CCC): native bladder or enterocystoplasty. METHODS. Retrospective monocentric study of pediatrics and adult patients who underwent a continent cystostomy between 1991 and 2020 with a continent catheterizable channel implanted in the native bladder's detrusor (D group) or the enterocystoplasty (EC group).
Status | Active, not recruiting |
Enrollment | 106 |
Est. completion date | June 2021 |
Est. primary completion date | January 1, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - Adult and pediatric patients who underwent a surgery for creation of a continent catheterizable channel - Between 1991 and 2020 - In the pediatric surgery or urology department at Nancy University Hospital Exclusion Criteria: - Ghoneim technique used for implantation |
Country | Name | City | State |
---|---|---|---|
France | Pierre Lecoanet | VandÅ“uvre-lès-Nancy |
Lead Sponsor | Collaborator |
---|---|
Central Hospital, Nancy, France |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Comparison of the long term continence between the two groups | Continence of the channel at last followup : as being strictly dry day and night between clean intermittent catheterizations (CIC). Patients requirring at leat one pad for leaking and also those with leaks wetting their clothes were considered incontinent as well as those whose interval between CIC was strictly less than 3 hours. | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02978638 -
Electrical Stimulation for Continence After Spinal Cord Injury
|
N/A | |
Enrolling by invitation |
NCT06429631 -
The Effect of CIC Education on QOL and Compliance With Mobile Application in Individuals With Spinal Cord Injury.
|
N/A | |
Completed |
NCT03573726 -
Use of a Diurnal Indwelling Urethral Catheter to Improve Quality of Life
|
N/A | |
Recruiting |
NCT06059066 -
Optimization of OnabotulinumtoxinA (BTX-A) Injection for the Treatment of Neurogenic Lower Urinary Tract Dysfunction
|
N/A | |
Completed |
NCT01429090 -
Bioavailability of Vagantin® Coated Tablets Relative to an Oral Methantheline Bromide Solution
|
Phase 1 | |
Recruiting |
NCT05587101 -
Neurogenic Lower Urinary Tract Symptoms in Patients With Multiple Sclerosis
|
||
Terminated |
NCT03843073 -
Connected Catheter- Safety and Effectiveness Study
|
N/A | |
Terminated |
NCT04059159 -
Connected Catheter - Safety and Effectiveness Study
|
N/A | |
Completed |
NCT05858840 -
Urinary Artificial Sphincter in Children
|
||
Completed |
NCT05861024 -
Urinary Calculi After Bladder Augmentation in Children
|
||
Completed |
NCT04074616 -
Reducing Anticholinergic Bladder Medication Use in Spinal Cord Injury With Home Neuromodulation
|
N/A | |
Completed |
NCT05683938 -
GentleCathâ„¢ Air Intermittent Catheter Smartwatch Real Life Pilot Study
|
||
Completed |
NCT04543552 -
A Comparative Analysis of Portable Bladder Scanner to Determine Age/ Volume Specific Accuracy in 0-6 Years of Children
|
||
Active, not recruiting |
NCT06247033 -
Efficacies of Different Managements in Patients With Overactive Bladder With Stroke
|
N/A | |
Withdrawn |
NCT01305681 -
Bacterial Properties With LoFric® Catheters During Clean Intermittent Catheterization
|
Phase 1/Phase 2 | |
Recruiting |
NCT04248322 -
Qualitative Assessment of the Impact of TTNS on QOL and Participation
|
||
Recruiting |
NCT05301335 -
Spinal COrd NeuromodulaTor by SpIneX and ScoNE to Treat NeurogeniC BladdEr - SCONE "CONTINENCE" Clinical Study
|
N/A | |
Recruiting |
NCT04924569 -
Continence Care Registry
|
||
Completed |
NCT01716624 -
Botox Versus Oxybutynin as First Line Treatment for the Poorly Compliant Pediatric Neurogenic Bladder
|
Phase 3 | |
Completed |
NCT01297647 -
Incidence of Urinary Tract Infection After Urodynamic Investigation
|
N/A |